No relevant news for Globus Medical Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 21 2025
0mins
Source: 8-K
Globus Medical Inc. experienced a price increase of 5.00% and reached a 5-day high.
However, there is no relevant news specifically mentioning Globus Medical or its subsidiaries. The broader market context shows that the Nasdaq-100 is up 1.35% and the S&P 500 is up 0.85%, indicating overall market strength. This suggests that the stock's movement may be influenced by sector rotation rather than any specific company news.
Investors should consider the broader market trends when evaluating the stock's performance, as the positive movement could be reflective of general market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 84.610
Low
87.00
Averages
101.00
High
114.00
Current: 84.610
Low
87.00
Averages
101.00
High
114.00
About GMED
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. It separates its products and services into two major categories: Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jim Cramer Expresses Negative Views on Multiple Companies
- Purecycle Technologies Struggles: Jim Cramer highlights that Purecycle Technologies has almost no revenue and is losing a fortune, suggesting investors should avoid this stock, indicating its unfavorable market perception.
- High Risk for Energy Vault Holdings: Cramer describes Energy Vault Holdings as a pure speculative stock that is also losing a fortune, implying its investment value is extremely low and investors should exercise caution.
- Everspin Technologies Overvalued: While Everspin Technologies is profitable, Cramer warns that its price-to-earnings ratio is at 90 times, advising investors to be careful, suggesting that market expectations for its future growth may be overly optimistic.
- Challenges for Rocket Companies: Cramer expresses a negative view on Rocket Companies, stating that even if Kevin Warsh might cut rates, the rising oil prices causing inflation make such cuts unlikely, indicating significant pressure on the company's future prospects.
See More
Globus Medical Q1 Earnings Beat Expectations but Stock Plummets
- Earnings Beat: Globus Medical reported an adjusted EPS of $1.12 for Q1, exceeding expectations by $0.20, indicating strong performance in the medical device sector, although the stock fell due to negative market reactions.
- Significant Revenue Growth: Total revenue reached $759.9 million in Q1, a 27% year-over-year increase, with $82.7 million coming from Nevro sales, demonstrating successful acquisition integration and enhancing market competitiveness.
- Substantial Net Income Increase: GAAP net income surged 64.7% to $124.3 million, reflecting ongoing growth in the U.S. spine business, particularly with a third consecutive quarter of 10% growth, showcasing the stability and growth potential of its operations.
- Optimistic Full-Year Guidance: Globus raised its full-year GAAP EPS guidance to $4.70 to $4.80 while reaffirming revenue guidance of $3.18 billion to $3.22 billion, indicating confidence in future performance despite recent stock price declines.
See More
Globus Medical Reports Strong Q1 2026 Earnings with Increased EPS Guidance
- Significant Revenue Growth: Globus Medical reported Q1 revenue of $759.9 million, reflecting a strong focus on expanding market share, which is expected to positively impact full-year results.
- Improved Profitability: The company achieved a non-GAAP earnings per share of $1.12 in Q1, exceeding expectations by $0.20, indicating successful operational efficiency and cost control, thereby enhancing investor confidence.
- Business Model Shift: The company is gradually shifting its robotics business towards lease and rental models, which is expected to drive future revenue growth, although short-term revenue volatility may pose challenges.
- Optimistic Outlook: Globus Medical reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP EPS forecast to $4.70 to $4.80, demonstrating management's confidence in future growth.
See More
2026 Economic Outlook and Uber Developments
- GDP Growth Slowdown: The GDP growth rate for Q1 2026 is only 0.7%, significantly lower than the previous estimate of 1.4%, indicating a sluggish economic recovery that may dampen investor confidence and negatively impact stock market performance.
- Rising Inflation Pressure: With inflation exceeding 3% in January, combined with slowing GDP growth, concerns about stagflation may arise, leading to reduced consumer spending and threatening corporate profitability.
- Surge in Oil Prices: West Texas Intermediate crude oil prices have surged from $57 on January 2 to $93, even exceeding $100 at times, increasing consumer energy expenditure pressure and potentially suppressing spending in other areas.
- Uber's Autonomous Driving Partnerships: Uber has recently formed partnerships with several companies, including Waymo and Lucid, indicating its proactive positioning in the autonomous driving sector, which may lay the groundwork for future market share growth.
See More
2026 Economic Outlook and Oil Price Fluctuations
- GDP Growth Slowdown: The GDP growth rate for Q1 2026 is only 0.7%, significantly lower than the previous estimate of 1.4%, indicating economic stagnation that may heighten investor concerns about future economic prospects.
- High Inflation Pressure: With inflation exceeding 3% in January, combined with low growth, market fears of stagflation are rising, which could negatively impact consumer spending and business investment decisions, further dragging down economic recovery.
- Surging Oil Prices Impact: As of the recording date, West Texas Intermediate crude oil prices have reached $93 per barrel, a significant increase from $57 on January 2, which may force consumers to cut back on other expenditures due to rising energy costs, affecting overall economic activity.
- Geopolitical Risks: The rise in oil prices is primarily driven by geopolitical conflicts rather than demand growth, particularly due to uncertainties surrounding Iran, which could lead to a more pessimistic economic outlook, necessitating close monitoring of related developments.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Jim Cramer Expresses Negative Views on Multiple Companies
- Purecycle Technologies Struggles: Jim Cramer highlights that Purecycle Technologies has almost no revenue and is losing a fortune, suggesting investors should avoid this stock, indicating its unfavorable market perception.
- High Risk for Energy Vault Holdings: Cramer describes Energy Vault Holdings as a pure speculative stock that is also losing a fortune, implying its investment value is extremely low and investors should exercise caution.
- Everspin Technologies Overvalued: While Everspin Technologies is profitable, Cramer warns that its price-to-earnings ratio is at 90 times, advising investors to be careful, suggesting that market expectations for its future growth may be overly optimistic.
- Challenges for Rocket Companies: Cramer expresses a negative view on Rocket Companies, stating that even if Kevin Warsh might cut rates, the rising oil prices causing inflation make such cuts unlikely, indicating significant pressure on the company's future prospects.
See More
Globus Medical Q1 Earnings Beat Expectations but Stock Plummets
- Earnings Beat: Globus Medical reported an adjusted EPS of $1.12 for Q1, exceeding expectations by $0.20, indicating strong performance in the medical device sector, although the stock fell due to negative market reactions.
- Significant Revenue Growth: Total revenue reached $759.9 million in Q1, a 27% year-over-year increase, with $82.7 million coming from Nevro sales, demonstrating successful acquisition integration and enhancing market competitiveness.
- Substantial Net Income Increase: GAAP net income surged 64.7% to $124.3 million, reflecting ongoing growth in the U.S. spine business, particularly with a third consecutive quarter of 10% growth, showcasing the stability and growth potential of its operations.
- Optimistic Full-Year Guidance: Globus raised its full-year GAAP EPS guidance to $4.70 to $4.80 while reaffirming revenue guidance of $3.18 billion to $3.22 billion, indicating confidence in future performance despite recent stock price declines.
See More
Globus Medical Reports Strong Q1 2026 Earnings with Increased EPS Guidance
- Significant Revenue Growth: Globus Medical reported Q1 revenue of $759.9 million, reflecting a strong focus on expanding market share, which is expected to positively impact full-year results.
- Improved Profitability: The company achieved a non-GAAP earnings per share of $1.12 in Q1, exceeding expectations by $0.20, indicating successful operational efficiency and cost control, thereby enhancing investor confidence.
- Business Model Shift: The company is gradually shifting its robotics business towards lease and rental models, which is expected to drive future revenue growth, although short-term revenue volatility may pose challenges.
- Optimistic Outlook: Globus Medical reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP EPS forecast to $4.70 to $4.80, demonstrating management's confidence in future growth.
See More
2026 Economic Outlook and Uber Developments
- GDP Growth Slowdown: The GDP growth rate for Q1 2026 is only 0.7%, significantly lower than the previous estimate of 1.4%, indicating a sluggish economic recovery that may dampen investor confidence and negatively impact stock market performance.
- Rising Inflation Pressure: With inflation exceeding 3% in January, combined with slowing GDP growth, concerns about stagflation may arise, leading to reduced consumer spending and threatening corporate profitability.
- Surge in Oil Prices: West Texas Intermediate crude oil prices have surged from $57 on January 2 to $93, even exceeding $100 at times, increasing consumer energy expenditure pressure and potentially suppressing spending in other areas.
- Uber's Autonomous Driving Partnerships: Uber has recently formed partnerships with several companies, including Waymo and Lucid, indicating its proactive positioning in the autonomous driving sector, which may lay the groundwork for future market share growth.
See More
2026 Economic Outlook and Oil Price Fluctuations
- GDP Growth Slowdown: The GDP growth rate for Q1 2026 is only 0.7%, significantly lower than the previous estimate of 1.4%, indicating economic stagnation that may heighten investor concerns about future economic prospects.
- High Inflation Pressure: With inflation exceeding 3% in January, combined with low growth, market fears of stagflation are rising, which could negatively impact consumer spending and business investment decisions, further dragging down economic recovery.
- Surging Oil Prices Impact: As of the recording date, West Texas Intermediate crude oil prices have reached $93 per barrel, a significant increase from $57 on January 2, which may force consumers to cut back on other expenditures due to rising energy costs, affecting overall economic activity.
- Geopolitical Risks: The rise in oil prices is primarily driven by geopolitical conflicts rather than demand growth, particularly due to uncertainties surrounding Iran, which could lead to a more pessimistic economic outlook, necessitating close monitoring of related developments.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
